Vanderbilt University Purchases Shares of 47,574 Sera Prognostics, Inc. (NASDAQ:SERA)

Vanderbilt University bought a new stake in Sera Prognostics, Inc. (NASDAQ:SERAFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 47,574 shares of the company’s stock, valued at approximately $284,000. Vanderbilt University owned 0.15% of Sera Prognostics at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. boosted its holdings in Sera Prognostics by 9.1% in the 1st quarter. BlackRock Inc. now owns 47,870 shares of the company’s stock worth $183,000 after acquiring an additional 3,974 shares during the period. Susquehanna International Group LLP purchased a new position in shares of Sera Prognostics in the first quarter valued at $39,000. Goldman Sachs Group Inc. purchased a new position in shares of Sera Prognostics in the first quarter valued at $41,000. Frontier Wealth Management LLC acquired a new stake in Sera Prognostics during the 1st quarter valued at $30,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Sera Prognostics during the 1st quarter worth $46,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Insider Buying and Selling at Sera Prognostics

In related news, insider Paul Kearney sold 4,984 shares of Sera Prognostics stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total value of $40,021.52. Following the completion of the transaction, the insider now directly owns 160,066 shares in the company, valued at $1,285,329.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sera Prognostics news, insider John J. Boniface sold 21,438 shares of Sera Prognostics stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $9.55, for a total value of $204,732.90. Following the completion of the transaction, the insider now owns 143,524 shares of the company’s stock, valued at $1,370,654.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Paul Kearney sold 4,984 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total transaction of $40,021.52. Following the sale, the insider now owns 160,066 shares of the company’s stock, valued at approximately $1,285,329.98. The disclosure for this sale can be found here. Insiders have sold 141,335 shares of company stock worth $1,255,192 in the last ninety days. 15.60% of the stock is owned by insiders.

Sera Prognostics Price Performance

SERA traded up $0.39 on Wednesday, reaching $9.60. The company’s stock had a trading volume of 32,790 shares, compared to its average volume of 242,197. Sera Prognostics, Inc. has a 1 year low of $1.52 and a 1 year high of $10.44. The business’s 50 day moving average is $8.67 and its 200 day moving average is $5.23. The stock has a market cap of $311.33 million, a price-to-earnings ratio of -7.94 and a beta of 1.49.

About Sera Prognostics

(Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.

See Also

Institutional Ownership by Quarter for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.